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Abstract 
Tight junctions are critically important for many physiological functions, including 
the maintenance of cell polarity, regulation of paracellular permeability and 
involvement in signal transduction pathways to regulate integral cellular processes. 
Furthermore, tight junctions enable epithelial cells to form physical barriers, which 
act as an innate immune mechanism that can impede viral infection. Viruses, in turn, 
have evolved mechanisms to exploit tight junction proteins to gain access to cells or 
spread through tissues in an infected host. Claudin family proteins are integral 
components of tight junctions, and are thought to play crucial roles in regulating their 
permeability. Claudins have been implicated in the infection process of several 
medically important human pathogens, including hepatitis C virus, dengue virus, 
West Nile virus and human immunodeficiency virus, among others. In this review, we 
summarize the role of claudins in viral infections, and discuss their potential as novel 
antiviral targets. A better understanding of claudins during viral infection may 
provide insight into physiological roles of claudins and uncover novel therapeutic 
antiviral strategies. 
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Introduction  
Tight junctions are highly specialized membrane domains that regulate paracellular 
permeability by forming intercellular barriers between epithelial cells. They also 
provide a physical barrier between apical and basolateral membrane domains of 
polarized epithelial cells, thus regulating compartmentalization of membrane 
molecules. As such, tight junctions maintain cell polarity [84] and have also been 
implicated in signal transduction pathways [36]. 
Integral membrane tight junction proteins include occludin (OCLN) [32], 
claudins (CLDNs) [31] and junctional adhesion molecule-1 (JAM-1) [63]. The 
claudin family is thought to be the most crucial for mediating formation and 
permeability of tight junctions. Structurally, claudins are 25-27 kDa proteins 
comprised of intracellular N-terminal and C-terminal tails, four transmembrane 
helices, two extracellular loops (large ECL1 and small ECL2) and one cytoplasmic 
loop (Figure 1). Typically, claudins have a signature sequence within ECL1 and a 
conserved C-terminal motif for binding to PDZ (PSD95, postsynaptic density protein; 
Dlg1, Drosophila disc large tumor suppressor; ZO-1, zonula occludens-1 protein) 
domains, enabling interaction with tight junction-associated scaffolding and adaptor 
proteins [49]. Homophilic and heterophilic interactions between different claudins as 
well as other TJ members mediate paracellular tightening at tight junctions, thus 
dictating permeability. 
The mammalian claudin family is comprised of 27 different members to date, 
although only 26 of these are found in humans [39]. Splice variants have been 
reported for some of these claudins, resulting in different protein isoforms with 
distinct expression patterns and function. Claudins are expressed in all epithelial 
tissues, although claudin family members have differential expression in different 
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tissues [39]. Although claudins are typically found in tight junctions, non-junctional 
localization of some claudins has been reported [37, 48, 78]. For example, CLDN1 
associates with tetraspanins on the hepatocyte cell surface to form tetraspanin 
enriched microdomain (TEM) [78]. Furthermore, CLDN1 directly associates with 
tetraspanin CD9 on Madin-Darby canine kidney cells and various carcinoma cells, 
and these CLDN1-CD9 complexes did not reside in tight junctions [52]. However, the 
physiological role of non-junctional claudin complexes remains to be identified. 
Tight junctions enable epithelial cells to form tight physical barriers that help 
to defend against infection. Some viruses counter this by infecting epithelial cells via 
receptors on the apical surface. Other viruses have evolved mechanisms to bypass 
epithelial cell barriers, either by using tight junction proteins as entry factors or by 
opening the tight junctions to facilitate their entry and dissemination. Indeed, tight 
junctions have been implicated in the infection process of several viruses (Table 1). 
In this review, we discuss the role of integral tight junction components, claudins, in 
viral infection and pathogenesis, and explore the potential of claudins as a target for 
antiviral therapy. Further studies into the role of claudins and tight junctions during 
viral infection will be important to better understand the mechanisms involved and to 
identify novel antiviral targets. 
 
Claudins and viral entry 
Hepatitis C virus 
Claudins were first recognized to play a role in viral entry in 2007, when CLDN1 was 
identified as a host factor for the hepatitis C virus (HCV) [25]. HCV, a positive sense 
single stranded RNA virus belonging to the Flaviviridae family, chronically infects 
approximately 130 million people worldwide. These individuals are at increased risk 
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for severe liver disease, such as cirrhosis and hepatocellular carcinoma. As an RNA 
virus, HCV exists as a highly variable population of quasispecies and is classified into 
seven major genotypes. HCV infects hepatocytes via a complex, multi-step process 
involving several host proteins, including glycosaminoglycans [8, 9, 57, 83], low 
density lipoprotein receptor [2], very-low-density lipoprotein receptor [95], 
tetraspanins CD81 [76] and CD63 [74], scavenger receptor class B type 1 [82, 103], 
tight junction proteins CLDN1 [25] and occludin [77], E-cadherin [58], receptor 
tyrosine kinases such as epidermal growth factor receptor (EGFR) [59, 106], serum 
response factor binding protein 1 [35], cholesterol transporter Niemann-Pick C1-like 
1 [80] and transferrin receptor 1 [62]. Following virion internalization [26, 68], fusion 
is triggered by low pH in the endosome [56]. The 9.6-kilobase genome is translated 
into a polyprotein of approximately 3000 amino acids [18], which then undergoes 
cleavage by cellular and viral proteases to generate 3 structural and 7 non-structural 
viral proteins. 
CLDN1 plays a central role in the HCV entry process [25]. It was identified as 
an HCV entry factor using an iterative expression cloning approach in which non-
hepatic 293T cells were transfected with a cDNA library derived from Huh7.5 
hepatoma cells [25]. CLDN1 was later shown to be important for cell-to-cell 
transmission of HCV [12], as well as cell-free entry. Mechanistically, CLDN1 is 
thought to form a co-receptor complex with CD81, an interaction that likely occurs on 
the basolateral hepatocyte surface and involves non-TJ CLDN1	  [43,	  44]. The CD81-
CLDN1 interaction involves the N-terminal portion of the ECL1 of CLDN1 [25]. 
Nine residues within the ECL1 of CLDN1 (W30-I32-D38-EGLW51-C54-C64) contributed 
to HCV entry [19, 25, 101]. Interestingly, these residues include W-GLW-C-C, the 
signature sequence shared by the majority of claudin family members	   [40]. In 
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particular, residues W30-I32-D38-EG49-W51 interacted with CD81 to promote HCV 
entry	   [20]. Formation of the CD81-CLDN1 co-receptor complex is regulated by 
EGFR [59], which recruits the GTPase Harvey rat sarcoma viral oncogene homolog 
(HRas) to mediate co-receptor interaction and downstream MAPK signaling	  [106].  
CLDN1 may also contribute to HCV entry by direct interaction with the HCV 
particle. HCV envelope glycoproteins E1 and E2 coimmunoprecipitate with CLDN1 	  
[101], and the E1E2 heterodimer was shown to recognize CLDN1 	  [23]. Furthermore, 
a genetic interaction between E1 and CLDN family members was recently described 
[47]. Given that HCV E2 interacts with CD81	   [46, 75]	   [51], both HCV envelope 
proteins may mediate binding to the co-receptor complex.  
CLDN6 and CLDN9 show high sequence homology to CLDN1 in the CD81-
interacting region, and have been proposed to function as complementary HCV co-
receptors	   [67]	   [104]. Although CLDN6 and CLDN9 are predominantly expressed in 
non-hepatic epithelial tissue during embryonic or neonate development	  [1, 69, 70, 87, 
94], their expression could be detected in human hepatoma cell lines, primary human 
hepatocytes and liver tissue by qPCR approaches [67, 104]. Expression of CLDN6 
and CLDN9 in CLDN-deficient 293T cells facilitated entry of HCV pseudoparticles 
(HCVpp) and cell culture-derived HCV (HCVcc) [67, 104]. Furthermore, CLDN9 
expression in CLDN1-deficient Bel7402 human hepatoma cells permitted HCV entry 
[104]. However, CLDN receptor usage appears to be genotype-dependent [41]. 
Genotypes 2, 5 and 7 were restricted to CLDN1, whereas other genotypes were able 
to efficiently use CLDN1 or CLDN6 for entry, as was shown in a CLDN-deficient 
cell line [41]. Interesting, strong selection pressure led to a single amino acid 
substitution in the E1 protein of a CLDN1-dependent strain of HCV (genotype 2), 
conferring the ability to enter hepatocytes via CLDN6 [47]. 
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As the CD81-CLDN1 co-receptor complex is essential for HCV entry, but 
lacks any known physiological (or pathological) function, therapies directed towards 
CLDN1 show great promise in preclinical models. Peptides derived from CLDN1 
sequences inhibit HCV entry in cell culture models [85]. Monoclonal antibodies that 
target CLDN1 interfere with the formation of the co-receptor complex	   [54]. These 
antibodies pan-genotypically inhibit cell-free infection and cell-to-cell transmission of 
HCV in human hepatoma cells	   [27, 54, 100]. Strikingly, anti-CLDN1 antibodies 
prevent HCV infection of human liver chimeric mice [30, 60] and were even able to 
cure chronically HCV-infected liver chimeric mice [60] without any detectable 
toxicity.  
One possible limitation for CLDN1-directed therapies is escape via CLDN6 or 
CLDN9 on hepatocytes. Indeed, CLDN1-specific antibodies only partially inhibited 
infection by HCV strains with broad CLDN tropism in CLDN6-expressing Huh7-
derived hepatoma cell lines [41].  However, the functional relevance of these findings 
is not clear. CLDN6 and CLDN9 expression could not be detected at the protein level 
in primary human hepatocytes [67], and CLDN6 protein expression could not be 
detected in liver sections [28]. Furthermore, anti-CLDN6 and anti-CLDN9 antibodies 
did not inhibit HCV infection of hepatoma cells or primary hepatocytes [28]. Most 
importantly, treatment with an anti-CLDN1 monoclonal antibody cured chronically 
infected human liver chimeric mice, without escape [60]. Overall, these findings 
suggest that low expression levels of CLDN6 and CLDN9 likely precludes their use 
as HCV entry factors, at least in the majority of patients. 
Dengue virus 
Like HCV, Dengue virus (DENV) is a positive sense single stranded RNA virus in the 
Flaviviridae family. The DENV genome is ~10.7-kb in length, encoding for 3 
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structural proteins (capsid, C; premembrane, prM; envelope, E) and 7 non-structural 
proteins [34]. Although DENV does not cause chronic infection, it is nonetheless a 
serious cause of morbidity and mortality around the world, particularly as it is a 
mosquito-borne virus endemic in over 100 countries [10]. In some patients, dengue 
virus infection leads to severe dengue hemorrhagic fever and shock syndrome 
(DHF/DSS) [55]. No specific antiviral therapy or vaccine is yet available. 
The molecular mechanisms of DENV entry into human cells remain unclear. 
Several host proteins have been proposed as DENV entry factors, including 
glycosminoglycans, lectins, glycosphingolipids and laminin-binding proteins [45]. 
Among these potential factors, CLDN1 was shown to be involved in DENV entry [17, 
33]. CLDN1 knockout studies and RNAi-mediated gene silencing in hepatoma cells 
inhibited DENV infection. The DENV prM protein binds to CLDN1 residues I32, C54 
and C64, which interestingly are also implicated in HCV infection [17]. Further 
studies are needed to elucidate the mechanistic role of CLDN1 during DENV entry 
and potential roles of other CLDN family members. 
 
Claudins and viral spread 
Viral infection and dissemination within a host is limited by epithelial cells, which 
line surfaces of organs and tissues to form a physical barrier enforced by tight 
junctions. Therefore, disruption of tight junctions in epithelial and endothelial barriers 
facilitates viral dissemination within the infected host. Several viruses, therefore, 
modulate expression of tight junction proteins such as claudins to enhance their 
dissemination. 
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West Nile virus 
Like HCV and DENV, West Nile virus is classified in the Flaviviridae family and has 
a single-stranded positive sense RNA genome of ~11 kb [13]. WNV is a mosquito-
borne virus capable of infecting the central nervous system, resulting in neurological 
disease in a minority of infected patients. Following mosquito transmission, the virus 
crosses several polarized cell layers, requiring a disruption of tight junctions by 
mechanisms that are not completely understood. One study in kidney tubules reported 
that WNV capsid protein induced the degradation of CLDN1, CLDN2, CLDN3 and 
CLDN4 by lysosomal proteases [66]. In endothelial cells, the disruption of tight 
junctions was found to be an indirect result of WNV infection, by secretion of matrix 
metalloproteases from infected astrocytes [96, 97]. Furthermore, matrix 
metalloprotease 9 was found to be involved in WNV infection of the brain by 
disrupting the blood brain barrier [98]. More recently, Xu and colleagues reported that 
CLDN1 and other tight junction proteins undergo endocytosis in WNV-infected 
endothelial and epithelial cells, resulting in the lysosomal degradation of tight 
junction proteins [99]. Interestingly, CLDN1 degradation was also observed in 
endothelial and epithelial cells infected with Japanese encephalitis virus (a related 
neurotropic flavivirus) [3], but not DENV [99]. For WNV, multiple mechanisms of 
tight junction disruption appear to be involved, ranging from WNV-induced 
endocytosis and degradation of tight junction proteins to immune cell-mediated 
production of matrix metalloproteases and proinflammatory cytokines. 
Human immunodeficiency virus  
Human immunodeficiency virus 1 (HIV-1) belongs to the Retroviridae family. HIV-1 
has a single stranded positive sense RNA genome, which undergoes reverse 
transcription into double stranded DNA that is integrated into the host genome. Thus, 
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HIV establishes a persistent, life-long infection. HIV-1 is transmitted via sexual 
routes, which requires the virus to cross genital or intestinal epithelial cell layers. 
HIV-1 typically infects CD4+ T cells, via interaction between viral gp120 and CD4 
[65]. Interestingly, one study reported that HIV-1 is capable of using CLDN7 as an 
entry factor in CD4-negative T cells independently of gp120 [105], although the 
physiological relevance remains unclear. To facilitate viral dissemination, HIV-1 has 
been shown to alter the expression of tight junction claudins in intestinal cell lines and 
primary genital epithelial cells [24, 72, 93]. HIV-1 infection can also lead to 
neuropathogenesis [11], following invasion of the central nervous system. Indeed, 
HIV-1 disrupts the tight junctions of the blood brain barrier [89], at least in part by 
downregulating CLDN5 expression [16], which may be the result of virus-induced 
post-translational modifications of CLDN5 [7]. This effect may be mediated by the 
viral Tat protein, which was shown to alter CLDN1 and CLDN5 expression in brain 
endothelial cells and in the brains of mice [4, 5]. In colonic cell lines and primary 
genital epithelial cells, gp120 was shown to disrupt CLDN1, CLDN2 and CLDN4 
expression and increase permeability [72]. Other tight junction proteins were also 
implicated [4]. Interestingly, disruption of tight junctions by HIV proteins was found 
to facilitate the paracellular spread of herpes simplex virus type 1 and type 2	  [86].  
Respiratory viruses 
Human rhinovirus (HRV), a single stranded positive sense RNA virus in the 
Picornaviridae family, is the main cause of the common cold and as such is one of the 
most common viral infections in humans [50]. Respiratory syncytial virus (RSV) is a 
single stranded negative sense RNA virus in the Paramyxoviridae family. It is a 
common cause of lower respiratory tract infections, particularly in children and 
immunocompromised individuals [42]. To establish infection, these viruses must 
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bypass the airway epithelium, a well-developed barrier regulated by tight junctions. 
Therefore, respiratory viruses have evolved mechanisms to disrupt or alter tight 
junctions. In primary human nasal epithelial cells, HRV was shown to decrease 
expression of CLDN1 and other tight junction components, thus increasing 
permeability [102]. Similarly, RSV decreased expression of CLDN1 in primary 
human nasal epithelial cells [64]. Conversely, however, RSV infection induced 
expression of CLDN4 and other tight junction components, which was suggested to 
facilitate viral assembly and budding at the apical membrane by promoting cell 
polarity [64].  
Gastrointestinal viruses 
Rotavirus (RV), a double stranded RNA virus in the Reoviridae family, infects the 
gastrointestinal tract and is a major causative agent of diarrhea in children [21]. RV 
infection of intestinal epithelial cell lines altered the distribution of CLDN1 and 
CLDN3, thus disrupting tight junctions and resulting in decreased permeability [22, 
71]. This effect was mediated at least in part by viral protein VP8 [71]. Given that RV 
uses integrins for cell entry [38], this disruption of the tight junctions was proposed to 
open paracellular spaces, allowing access to the receptors. This likely contributes to 
pathogenesis by disrupting the intestinal lining. 
Norovirus (NV), a single stranded positive sense RNA virus in the 
Caliciviridae family, is the most common cause of viral gastroenteritis [79]. As for 
RV, infection with NV leads to a reduction in expression of tight junction proteins, 
including CLDN4 and CLDN5 [92]. The resulting epithelial barrier dysfunction 
contributes to pathogenic effects of infection, such as diarrhea. 
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Beyond claudins: Tight junctions and viral infection 
Although claudins are key players in tight junction physiology, other proteins from 
different families contribute to tight junction structure and function. The Junctional 
Adhesion Molecules (JAM-A, JAM-B and JAM-C) as well as the Coxsackievirus and 
Adenovirus Receptor (CAR) [29] are part of the immunoglobulin superfamily. CAR 
was the first tight junction protein shown to be involved in viral entry, and mediates 
the entry of both adenoviruses and coxsackieviruses, by different mechanisms [15]. 
JAM-A, another tight junction component, is important for the entry and 
internalization of reoviruses [14], such as RV [91], as well as feline calicivirus [61]. 
Indeed, viruses from several different families use tight junction proteins either for 
entry, dissemination or egress	  [90]. Further research into tight junctions with respect 
to viral infection will allow for a better understanding of viral 
replication/dissemination strategies and may provide targets for novel therapeutic 
strategies. 
 
Conclusions and perspectives 
As key components of tight junctions, claudins are critical for the regulation of tight 
junction structure and function. Given that claudins regulate paracellular permeability 
and form barriers between epithelial cells, several viruses evolved mechanisms to use 
claudins during their replication cycle or to disseminate within the host. As such, 
claudins are attractive antiviral targets. Indeed, antibodies and peptides targeting 
CLDN1 have been shown to be highly effective against HCV [27, 30, 54, 60, 73, 85, 
100]. These antibodies are thought to block formation of the nonphysiological 
CLDN1-CD81 co-receptor complex during HCV entry, and thus lack any obvious 
toxic effects for the host. The potential of claudins as antiviral targets in the context of 
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other viral infections remains to be established. Furthermore, claudins are implicated 
in the pathology of several diseases. Further research into the roles of claudins in viral 
infection will provide insight into their physiological roles, opening avenues for novel 
antiviral and therapeutic strategies. 	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Table 1. Claudin usage by different viruses.  
Virus Claudin member Function Reference(s) 
Hepatitis C virus CLDN1, CLDN6, 
CLDN9 
 
Viral entry into hepatocytes, cell-to-cell 
transmission 
[19, 25, 26, 41, 
67, 104] 
Dengue virus CLDN1 
 
Viral entry  
 
[17, 33] 
West Nile virus CLDN1, CLDN2, 
CLDN3, CLDN4 
Degradation of claudins facilitates viral 
dissemination into the brain 
 
[66, 96, 97, 99] 
Japanese encephalitis 
virus 
CLDN1 Degradation of CLDN1 likely facilitates viral 
dissemination 
 
[3] 
Human 
immunodeficiency 
virus 
CLDN7 
 
CLDN1, CLDN2, 
CLDN4, CLDN5 
Viral entry into CD4(-) T cells in gp120-
independent manner 
Degradation of claudins facilities viral 
dissemination 
 
[105] 
 
[4, 5, 7, 16, 24, 
72, 93] 
Human rhinovirus CLDN1 Degradation of CLDN1 facilitates viral access 
to receptors 
 
[102] 
 
Respiratory syncytial 
virus 
CLDN1 
 
CLDN4 
Degradation of CLDN1 facilitates viral access 
to receptors 
Induction of CLDN4 expression facilitates 
viral budding at apical membrane 
 
[64] 
 
[64] 
Rotavirus CLDN1, CLDN3 Disruption of claudin localization facilitates 
viral access to receptors 
 
[22, 71] 
Norovirus CLDN4, CLDN5 Reduction in claudin expression may enhance 
viral infection/dissemination 
 
[92] 
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Figure 1. Homology model showing the general structure of CLDN1 as a 
representative claudin. Claudin signature sequence residues within ECL1 (W-GLW-
C-C) are shown in red with side chains. The homology model was generated using the 
crystal structure of murine CLDN19 [81] as a template in SWISS-MODEL [6]. 
CLDN19 is closely related to CLDN1 [53]. The structure was rendered in PyMol 
[88]. ECL1, extracellular loop 1; ECL2, extracellular loop 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ECL1 ECL2 
N-terminal 
C-terminal 
Transmembrane 
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